

Curriculum vitae with track record – Stian Knappskog

Personal information

First name, Surname:	Stian Knappskog		
Date of birth:	21.09.1977	Sex:	Male
Nationality:	Norwegian		
Researcher unique identifier(s) (ORCID, ResearcherID, etc.):	ORCID: 0000-0002-4153-1655		
URL for personal website:	www.uib.no/en/persons/Stian.Knappskog		

Education

Year	Faculty/department - University/institution - Country
2007	Ph.D., Institute of Medicine, University of Bergen, Norway
2003	Cand. Scient., Department of Molecular Biology, University of Bergen, Norway

Positions - current and previous

Year	Job title – Employer - Country
2019 →	<i>Professor (100%), Dept. of Clinical Science, University of Bergen, Norway.</i>
2015 →	<i>Senior Research Fellow (20%), Dept. of Oncology, Haukeland University Hospital, Norway.</i>
2015-2019	<i>Senior Research Fellow, Dept. of Clinical Science, University of Bergen, Norway.</i>
2012-2014	<i>Senior Scientist, Dept. of Clinical Science, University of Bergen, Norway.</i>
2011-2012	<i>Visiting Scientist, Cancer Genome Project, Wellcome Sanger Institute, Cambridge, UK.</i>
2007-2011	<i>Post doctor, Institute of Medicine, University of Bergen, Norway.</i>

Project management experience

Year	Project owner - Project - Role - Funder
Received	Project PI
2018	Open project grant, the Norwegian Research Council (FRIMEDBIO) (1M EUR)
2018	Open project grant, the Norwegian Health Region West (500K EUR)
2017	Open project grant, the Norwegian Cancer Society (900K EUR)
2016	Open project grant, the Norwegian Health Region West (500K EUR)
2016	Running cost grant, the Norwegian Cancer Society (45K EUR)
2015	Recruitment grant, Bergen Research Foundation & University of Bergen (1.8M EUR)
2015	Senior Researcher Fellowship, the Norwegian Cancer Society (Pink ribbon) (400K EUR)
2014	“Fellesløftet”, the Norwegian Research Council & University of Bergen (750K EUR)
2014	PhD-position & running costs, the Norwegian Cancer Society (200K EUR)
2014	Running cost grant, the Norwegian Cancer Society (28K EUR)
2011	Project grant, L.Meltzer Høyskolefond (30K EUR)
2011	Recruitment grant, Bergen Medical Research Foundation (370K EUR)
2011	Mobility grant, Norwegian Cancer Society (17K EUR)

	Project co-PI
2017	“Behandling”, the Norwegian Research Council (1.5M EUR)
2017	K.G.Jebsen Center for Genome-directed therapy in cancer (1.8M EUR)
2015	PETREMAC clinical trial, Norwegian Health Region West (1.7M EUR)
2009	Infrastructure establishment grant, Bergen Research Foundation (1.3M EUR)

Supervision of students

Master's students	Ph.D. students	University/institution - Country
4	12	University of Bergen, Norway

Other relevant professional experiences

Year	Description - Role
	Institutional responsibilities
2013-2020	12 times member of committee, PhD mid-way evaluations, Dept of Clinical Science, University of Bergen
2018 →	Leader, Bergen postgraduate school of clinical medical research
2018-2020	External evaluator -candidates for PhD, post doc and researcher positions, Dept. of Biomedicine
2014-2016	Member of committee planning advanced biobanking infrastructure in Health Region Bergen / Haukeland University Hospital.
2014	External evaluator -candidates for technical position, Dept. of Biomedicine
2014	External evaluator-candidates for post doc position, Dept. of Biomedicine
2013-2014	Representative for Health Region West in a Norwegian national advisory commission on personalised medicine.
2010	External evaluator -candidates for post doc position, Dept. of Molecular Biology
2009 →	Laboratory manager, Mohn Cancer Research Laboratory, Norway
2007-2009	Representative for Section of Oncology, Institute of Medicine, University of Bergen, during planning and building of the Laboratory Building Haukeland University Hospital.
	Commissions of trust -evaluation of candidates
2019	Member of evaluation committee and 2 nd opponent, PhD-defence, Ulrike Neckmann, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
2015	Member of evaluation committee and 2 nd opponent, PhD-defence, Andreas M. Hoff, Faculty of Medicine, University of Oslo, Norway.
2015	Member of evaluation committee and 2 nd opponent, PhD-defence, Mari Tinholt, Faculty of Medicine, University of Oslo, Norway.
2015	External evaluator of thesis for the medical student research program, Arne V Pladsen, Faculty of Medicine, University of Oslo, Norway.
2013	Member of evaluation committee and 2 nd opponent, PhD-defence, Deeqa A. Ali, Faculty of Medicine, University of Oslo, Norway.

	Commissions of trust -evaluation of grant applications
2020	External referee for grant application for Advanced Grant, the European Research Council (ERC)
2018-2020	External referee and committee leader for grant applications to the Central Norway Regional Health Authorities, Norway.
2016-2017	External referee for grant applications to the Central Norway Regional Health Authorities, Norway.
2016	External referee for grant application to Breast Cancer Now, UK.
2015	Member of committee evaluating grant applications to the Norwegian Cancer Society
2014	Member of committee evaluating grant applications to the Norwegian Cancer Society
2013	External referee for grant applications to the Foundation for Polish Science.
2012	External referee for grant applications to the Portuguese Foundation for Science and Technology.

Track record

My current bibliometry is as follows:

- Publications in peer-reviewed scientific journals:	95
in journals with impact factor >15:	11
- Citations (Web of Science Core Collection / Google scholar):	>8,300 / >12,000
- H-index (Web of Science Core Collection / Google scholar):	30 / 34
- Chapters in scientific books:	1
- Posters at international meetings:	45
- Oral presentations at international meetings:	19

Out of the 95 published papers, 76 are original articles, 1 is a large consortium paper and 18 reviews or letters. Eleven publications are published in high impact journals (impact factor >15, including 2 first authorships in *Cancer Cell*, a last authorship in *Annals of Int. Medicine* and co-authorships in *Nature* (x4), *Nature Medicine*, *Nature Genetics*, *Science* and *Annals of Oncology*.

10 SELECTED PAPERS (2010 – 2020)

1. **Knappskog, S.**, Bjørnslett, M., Myklebust, L.M., Huijts, P., Vreeswijk, M., Edvardsen, H., Guo, Y., Zhang, X., Yang, M, Ylisaukko-oja, S.K., Alhopuro, P., Arola, J, Tollenaar R.A.E.M., van Asperen, C., Seynaeve C., Staalesen, V., Chrisanthar, R., Løkkevik, E., Salvesen, H.B., Evans, D.G., Newman, W.G., Lin, D., Aaltonen, L.A., Børresen-Dale, A-L., Tell, G.S., Stoltenberg, C., Romundstad, P., Hveem, K., Lillehaug, J.R., Vatten, L., Devilee, P., Dørum, A., and Lønning, P.E. The MDM2 promoter SNP285C/309G haplotype diminish Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. *Cancer Cell*. 19: 273-282. (2011) (Citations: 80)
2. **Knappskog, S.**, Chrisanthar, R., Løkkevik, E., Anker, G., Østenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., Leirvaag, B., Miletic, H., and Lønning, P.E. Low expression levels of ATM may substitute for CHEK2 / TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. *Breast Cancer Research*. 14(2); R47 doi:10.1186/bcr3147. (2012) (Citations: 40)
3. Alexandrov, L., Nik-Zainal, S., Wedge, D.C., Aparicio, S., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A-L., Boyault, S., Burkhardt, B., Butler, A.P., Caldas, C., Davies, H.R., Desmedt, C., Eils, R., Eyfjörð, J.E., Foekens, J.A, Greaves, M., Hosoda, F., Hutter, B., Illic, T., Imbeaud, S., Imielinsk, M., Jäger, N., Jones, D.T.W., Jones, D., **Knappskog, S.**, Kool, M., Lakhani, S.R., López-Otín, C., Martin, S., Munshi, N.C., Nakamura, H., Northcott, P.A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J.V., Puente, X.S., Raine, K., Ramakrishna, M., Richardson, A.L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T.N., Span, P.N., Teague, J.W., Totoki, Y., Tutt, A., Valdés-Mas, R., van Buuren, M.M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L.R., Australian Pancr. Ca. Genome Init., ICGC Breast Ca. Cons., ICGC MML-Seq Cons., ICGC PedBrain, Zucman-Rossi, J., Futreal, P.A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S.M., Siebert, R., Campo, E., Shibata, T., Pfister, S.M., Campbell, P.J., Stratton, M.R. Signatures of mutational processes in human cancers. *Nature*. 500 (7463): 415-421. (2013) (Citations: 4260)
4. Nik-Zainal, S., Wedge, D.C., Alexandrov, L., Petljak, M., Butler, A., Bolli, N., Davies, H.R., **Knappskog, S.**, Martin, S., Papaemmanuil, E., Ramakrishna, M., Shlien, A., Simoncic, I., Xue, Y., Tyler-Smith, C., Campbell, P.J. and Stratton, M.R. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. *Nature Genetics*. 46(5): 487-491. (2014) (Citations: 161)

5. Yates, L.R., Gerstung, M., **Knappskog, S.**, Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L.B., Larsimont, D., Davies, H., Li, Y., Ju, Y.S., Ramakrishna, M., Haugland, H.K., Lilleng, P.K., Nik-Zainal, S., McLaren, S., Butler, A., Martin, S., Glodzik, D., Menzies, A., Raine, K., Hinton, J., Jones, D., Mudie, L.J., Jiang, B., Vincent, D., Greene-Colozzi, A., Adnet, P.-Y., Fatima, A., Maetens, M., Ignatiadis, M., Stratton, M.R., Sotiriou, C., Richardson, A.L., Lønning, P.E., Wedge, D.C., and Campbell, P.J. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. *Nature Medicine*. 21(7): 751-759. (2015) (Citations: 386)
6. Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L.B., Martin, S., Wedge, D.C., Van Loo, P., Ju, Y.S., Smid, M., Brinkman, A.B., Morganella, S., Aure, M.R., Lingjærde, O.C., Langerød, A., Ringnér, Ahn, S-M., Boyault, S., Brock, J.E., Broeks, A., Butler, A., Desmedt, C., Dirix, L., Dronov, S., Fatima, A., Foekens, J.A., Gerstung, M., Hooijer, G.K.J., Jang, S.J., Jones, D.R., Kim, H-Y., King, T.A., Krishnamurthy, S., Lee, H.J., Lee, J-Y., Li, Y., McLaren, S., Menzies, A., Mustonen, V., O'Meara, S., Pauporté, I., Pivot, X., Purdie, C., Raine, K., Ramakrishna, K., Rodríguez-González, F.G., Romieu, G., Sieuwerts, A.M., Simpson, P.T., Shepherd, R., Stebbings, I., Stefansson, O.A., Teague, J., Tommasi, S., Treilleux, I., Van den Eynden, G.G., Vermeulen, P., Vincent-Salomon, A., Yates, L., Caldas, C., van't Veer, L., Tutt, A., **Knappskog, S.**, Tan, B.K.T., Jonkers, J., Borg, Å., Ueno, N.T., Sotiriou, C., Viari, A., Futreal, P.A., Campbell, P.J., Span, P.N., Van Laere, S., Lakhani, S.R., Eyfjord, J.E., Thompson, A.M., Birney, E., Stunnenberg, H.G., van de Vijver, M.J., Martens, J.W.M., Børresen-Dale, A-L., Richardson, A.L., Kong, G., Thomas, G., and Stratton, M.R. Landscape of somatic mutations in 560 breast cancer whole genome sequences. *Nature*. 534: 47-54. (2016) (Citations: 792)
7. Yates, L.R.* , **Knappskog, S.*** , Wedge D.C., Martincorena I., Alexandrov L.B., Van Loo P., Haugland, H.K., Lilleng P.K., Gundem G., Gerstung, M., Gonzalez, S., Pappaemmanuil, E., Gazinska, P, Bhosle, S.G., Jones, D., Raine, K., Mudie, L., Latimer, C., Sawyer, E., Desmedt, C., Sotiriou, C., Stratton, M.R., Sieuwerts, A., Richardson, A., Tutt, A., Lønning, P.E., Campbell, P.J. Genomic Evolution of Breast Cancer Metastasis and Relapse. *Cancer Cell*. 32: 169-184(2018) (Citations: 197)
* shared first authorship.
8. Lønning, P.E Berge, E.O., Bjørnslett, M., Minsaas, L., Chrisanthar, R., Høberg-Vetti, H., Dulary, C., Busato, F., Bjørneklett, S., Eriksen, C., Kopperud, R., Axcrona, U., Davidson, B., Bjørge, L., Evans, D.G., Howell, A., Salvesen, H.B., Janszky, I., Hveem, K., Romundstad, P., Vatten, L., Tost, J., Dørum, A. **Knappskog, S.** White blood cell BRCA1 promoter methylation status and ovarian cancer risk. *Annals of Internal Medicine*. 168(5): 326-334. (2018) (Citations: 11)
9. Birkeland, E., Zhang, S., Poduval, D., Geisler, J., Nakken, S., Vodak, D., Meza-Zepeda, L.A., Hovig, E., Myklebost, O., **Knappskog, S.**, Lønning P.E. Patterns of genomic evolution in advanced melanoma. *Nature Communications*. 9: 2665 (2018) (Citations: 17)
10. Eikesdal, H.P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E.S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., Venizelos, A., Minsaas, L., Leirvaag, B., Gudlaugsson E.G., Vintermyr, O.K., Aase, H.S., Aas, T., Balmaña, J., Serra, V., Janssen, E.A.M., **Knappskog, S.**, Lønning, P.E. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Annals of Oncology*. 32(2): 240-249. (2021) (Citations: 0)

PATENTS

1. Pendino, F., de la Grange, P., Lillehaug, J.R., Aloysius, T.A., **Knappskog, S.**: Methods for determining a prognosis for survival for a patient with leukemia. Bergen Teknologioverføring. Jan, 26. 2012: WO 2012/010661.
2. Pendino, F., Lillehaug, J.R., Aloysius, T.A., **Knappskog, S.**: Methods for determining a prognosis for survival for a patient with breast cancer. Bergen Teknologioverføring. Nov, 30. 2011: EP2389450 A1.

PRIZES AND AWARDS

- | | |
|------|--|
| 2017 | Best user participation in Science, the Norwegian Cancer Society. National award (2500 EUR) |
| 2016 | Konsul Søren Falch and Øyenlege Sigurd Falch junior award for young scientists - 2016, University of Bergen. Local award (5500 EUR). |
| 2016 | Young scientist of the year - 2016, Norwegian Oncology Forum. National award (5500 EUR). |

REVIEW WORK FOR SCIENTIFIC JOURNALS

PLoS ONE (2011, 2014, 2016), BMC Cancer (2012, 2013, 2014, 2016), Annals of Oncology (2013), Familial Cancer (2013), Molecular Biology Reports (2014), Journal of Therapeutics and Clinical Risk Management (2014), Journal of Biotechnology (2014), Tumor Biology (2014, 2015, 2016), Biomarkers (2014), JNCI – Journal of the National Cancer Institute (2014), Oncotarget (2014, 2015, 2016), Journal of Obstetrics and Gynaecology Research (2014), Cancer Biomarkers (2015), DNA Repair (2015), Gene (2015), Acta Oncologica (2015), Molecular Diagnosis and Therapy (2015, 2016), BMC Medical Genetics (2015), Scientific Reports (2015, 2016), BBA (2015), Meta Gene (2016), IUBMB (2016), Disease Markers (2016), Translational Oncology (2017), Environmental Pollution (2017), International Journal of Experimental Pathology (2017), Clinical and Experimental Medicine (2017), Scandinavian Journal of Immunology (2018), Cell death & disease (2018), Biomedicine & Pharmacotherapy (2019), International Journal of Cancer (2019), Cancer Medicine (2020), Theranostics (2020), BBA Molecular Cell Research (2020), Experimental Cell Research (2020), Redox Biology (2020), Genomics (2020), Biomedicine & Pharmacotherapy (2020), Histopathology (2021)

SCIENCE COMMUNICATION IN MEDIA

- National broadcasters (NRK TV-News, TV2, NRK radio)
- National and regional newspapers (VG, BT, BA, DM)
- International newspapers / broadcasters (Daily Express, RTBF)